Catalyst Pharmaceutical CPRX Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's net unrealized gains (losses) on securities still held?
- Catalyst Pharmaceutical (CPRX) reported net unrealized gains (losses) on securities still held of $8K in Q1 2026.
- How has Catalyst Pharmaceutical's net unrealized gains (losses) on securities still held changed year-over-year?
- Catalyst Pharmaceutical's net unrealized gains (losses) on securities still held increased by 109.9% year-over-year, from -$81K to $8K.
- What is the long-term trend for Catalyst Pharmaceutical's net unrealized gains (losses) on securities still held?
- Over 4 years (2021 to 2025), Catalyst Pharmaceutical's net unrealized gains (losses) on securities still held has grown at a -22.7% compound annual growth rate (CAGR), from -$179K to -$64K.
- What does net unrealized gains (losses) on securities still held mean?
- This represents the change in the fair value of investment securities held by the company that have not yet been sold. It captures market-driven fluctuations in the value of the company's investment portfolio that are excluded from net income. Tracking this metric is essential for assessing the impact of market volatility on the company's total equity and financial position.